Yervoy Launch in Europe gets clinicians excited about melanoma combo with Zelboraf
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has begun its roll-out of the novel advanced melanoma treatment Yervoy (ipilimumab) in Europe, as Genentech and Plexxikon received their first approvals in the US for another promising treatment, Zelboraf (vemurafenib). The two drugs, which are now being tested for use in combination, are heralding a new era in the treatment of melanoma, ending a period of 30 years' stagnation in drugs for the disease.